Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma

Chest

Volumn 121, Issue 2, 2002, Pages 480-487

  De Bree, Eelco ^a   Van Ruth, Serge ^a   Baas, Paul ^a   Rutgers, Emiel J Th ^a   Van Zandwijk, Nico ^a   Witkamp, Arjen J ^a   Zoetmulder, Frans A N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cytoreductive; Hyperthermia; Intrapleural chemotherapy; Intrathoracic chemotherapy; Malignant mesothelioma; Pleural malignancy; Surgery; Thymic carcinoma; Thymoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; EARLY CANCER; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; INTRAOPERATIVE PERIOD; LUNG PERFUSION; MALE; MEDIASTINUM CANCER; MORBIDITY; MULTIMODALITY CANCER THERAPY; PLEURA CANCER; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; REOPERATION; SAFETY; SURGICAL DRAINAGE; SURGICAL WOUND; THORACOTOMY; THORAX SURGERY; THYMOMA; TREATMENT OUTCOME;

EID: 0036172986     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.2.480     Document Type: Article

References (46)

1. Intraperitoneal chemotherapy
2. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis
3. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines
4. Clinical hyperthermia and chemotherapy
5. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin
6. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei
7. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer
8. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVIHIPEC) in patients with recurrent ovarian cancer: A feasibility pilot
9. Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy
10. Treatment of peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP)
11. Results of treatment of 33 patients with peritoneal mesothelioma
12. Intrapleural perfusion hyperthermo-chemotherapy for malignant pleural dissemination and effusion
13. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: A feasibility and pharmokinetic study
14. Intrathoracic hyperthermochemotherapeutic perfusion for intrathoracic malignancies in gastric cancer
15. A new device for the treatment of pleural malignancies: Intrapleural chemohyperthermia preliminary report
16. Surgical resection combined with intrathoracic hyperthermic perfusion for thymic carcinoma with an intrathoracic disseminated lesion: A case report
17. Clinical and pathological predictors of survival in patients with thymoma
18. Controversies in the management of malignant thymoma
19. Thymoma: State of the art
20. Nonsurgical management of malignant thymoma
21. Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970; a population-based study
22. Mesothelioma: New concepts in diagnosis and management
23. Management of malignant pleural mesothelioma: A critical review
24. Photodynamic therapy as adjuvant in surgically treated pleural malignancies
25. Malignant pleural mesothelioma
26. Malignant pleural mesothelioma
27. A review of chemotherapy trials for malignant mesothelioma
28. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions: LCGS trial 861
29. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions
30. Diffuse malignant mesothelioma of the pleura-intrapleural treatment with doxorubicin
31. High dose intrapleural cisplatin in case of malignant pleural mesothelioma: Clinical observations and pharmacokinetic analyses
32. Trials in malignant mesothelioma: LCSG 851 and 882
33. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The UCLA experience
34. A phase II study of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant mesothelioma
35. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma
36. Intrapleural pirarubicin (4′-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion
37. Pattern of failure following treatment of pseudomyxoma peritonei of appendiceal origin
38. Methodologic considerations in treatment using intraperitoneal chemotherapy
39. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues
40. Hyperthermic intraperitoneal doxorubicine: Pharmacokinetics, metabolism, and tissue distribution in a rat model
41. Natural history and treatment of malignant thymoma
42. Congestive heart failure in rabbits after a single intrapleural administration of a low dose of doxorubicin or epirubicin
43. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
44. Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging
45. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma
46. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: A randomized trial of local radiotherapy